The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in approximately 15-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission and immunophenotype of relapsed ALL. Bone marrow (BM) and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than isolated extramedullary or late relapse (>30 months from diagnosis). Also persistence of minimal residual disease (MRD) at the end of induction or consolidation therapy predicts poor outcome, since children with detectable MRD are more likely to relapse than those in molecular remission, even after allogeneic hematopoietic stem cell transplantation (HSCT). We offer HSCT to any child with high-risk features, since these patients are virtually incurable with chemotherapy alone. By contrast, we treat children with first late BM relapse of B-cell precursor ALL and good clearance of MRD with a chemotherapy approach. We use both systemic and local treatment for extramedullary relapse, mainly represented by radiotherapy and, in case of testicular involvement, by orchiectomy. Innovative approaches, including new agents or strategies of immunotherapy, are under investigation in trials enrolling patients with resistant or more advanced disease.
Introduction
Currently, around 80-85% of children with acute lymphoblastic leukemia (ALL) can be cured through the application of reliable prognostic factors permitting use of risk-oriented treatment protocols. [1] [2] [3] [4] The most common cause of treatment failure in pediatric ALL remains relapse: it occurs in approximately 15-20% of patients, resulting in an incidence of about 0.7/100,000 children per year in Europe. Thus, relapsed ALL is the fourth most common childhood malignancy, and the number of children with ALL who experience treatment failure each year is similar to the number of children with newly diagnosed acute myeloid leukemia (AML) or rhabdomyosarcoma. 5 With intensive combination chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), 30-50% of all children with relapsed ALL can be cured. [6] [7] [8] [9] [10] [11] [12] Thus, most children still die despite aggressive chemo-radiotherapy approaches, including transplantation, and novel salvage regimens are needed.
Over the last decade, important biological and clinical differences have been identified between leukemic cells at diagnosis and relapse, including the acquisition of new chromosomal abnormalities and gene mutations, and reduced responsiveness to chemotherapeutic agents. 10, 13 Moreover, reliable and sound criteria have been validated to identify subgroups of patients at higher risk of death due to leukemia progression and the use of allogeneic HSCT has improved their outcome. Novel approaches include new formulations of existing chemotherapeutic agents, new antimetabolites and nucleoside analogs, monoclonal antibodies directed against leukemia-associated antigens and molecularly-targeted drugs. 14, 15 However, expedited development of drugs with high probability of activity in relapsed ALL has yet to be optimized.
In this paper, we summarize the most recent knowledge on the pathophysiology of ALL recurrence, the criteria used for patient stratification, and the outcome reported by the most credited pediatric
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Pathophysiology of relapse
Most ALL relapses occur during treatment or within the first 2 years after treatment completion, although relapses have been reported to occur even after 10 years from diagnosis. 5, 16 The majority of relapses occur in the bone marrow (BM), either in an isolated form or combined with involvement of another site, mainly central nervous system (CNS) or the testes; isolated CNS or testicular relapse or, much less frequently, relapse involving other extramedullary sites may also occur.
Leukemia relapse represents the outgrowth of a clonal cell population not completely eliminated by treatment. Sophisticated analyses on rearrangements of immunoglobulin or T-cell receptor (TCR)
genes typical of ALL clones at diagnosis and recurrence may help clarify the origin of leukemia recurrence. Indeed, each case of ALL harbors a unique rearrangement of immunoglobulin or TCR genes. Matched-pair analyses have detected immunoglobulin and TCR phenotypic shifts from diagnosis to relapse, but retrospective studies suggested that the relapsing clone is present in the initial specimen and persists in greater copy numbers than others, indicating selection of a preexisting drug-resistant clone. 10 Although the relapsing clone may be undetectable after postinduction therapy, it can be initially evidenced in BM as minimal residual disease (MRD) and subsequently as overt disease recurrence. This has led to the hypothesis that many leukemia relapses may be the result of the selection of a relatively resistant clone already present at initial diagnosis rather than generation of a novel clone by mutation. 10 By contrast, late relapses may represent de novo development of a second leukemia from a common premalignant clone. In this respect, very late relapses of TEL/AML1-positive ALL may represent a new event occurring in a
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From quiescent leukemic cell that harbors an otherwise silent fusion gene and that has escaped eradication during initial therapy. 17 Based on TCR gene rearrangement status, common clonal origins between diagnosis and relapse were also documented in the majority of BM T-ALL recurrences, which occur early in 90% of cases. 18 In the few cases of late T-ALL relapses, TCR gene rearrangement sequences changed between diagnosis and relapse in more than one third of cases, thus suggesting that these recurrences should be considered as a second T-ALL rather than a resurgence of the original clone.
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A more recent approach to address the issue of the origin of relapsed ALL is based on the use of genome-wide DNA copy number analysis on matched samples collected at diagnosis and relapse. 13 In a seminal study, Mullighan et al. demonstrated that the majority of relapse samples harbored at least some of the genomic copy number abnormalities (CNA) present at diagnosis. 13 More in detail, in only a minority of ALL cases (6%) the relapse clone represents the emergence of a genetically distinct and thus unrelated second leukemia. 13 In the remaining cases, either there were no differences in CNA between the diagnostic and relapse clones (8%), or relapse represented the clonal evolution of the diagnosis leukemic population (34%), or the relapse clone acquired new lesions, while retaining some, but not all, of the lesions found in the diagnostic sample (52%). 13 Many of the genetic alterations that emerge in the predominant clone at relapse have been reported to involve genes implicated in treatment resistance, such as CDKN2A/B and IKZF1. 19 Notably, a recent study on gene expression analysis revealed a signature of differentially expressed genes from diagnosis to relapse that varies in early (< 36 months) and late (> 36 months) ALL relapses. 20 CNS relapse has been reported to occur in 3-8% of patients. 21 Leukemic cells may enter the CNS from the BM of the skull into the subarachnoid space via the bridging veins or the cerebrospinal fluid (CSF) via the choroid plexus, invade cerebral parenchyma via brain capillaries, or infiltrate the leptomeninges via bony lesions of the skull. 21 Leukemia blasts can also disseminate through nerve 21 It is noteworthy that recently published evidence suggests that sub-microscopic involvement of the BM with leukemia is a frequent finding in patients with isolated CNS relapse. 25 An isolated testicular relapse is defined as unilateral or bilateral testiculomegaly, with biopsyproven testicular involvement in the absence of BM disease, e.g., M1 status with less than 5%
blasts. The testes are conventionally considered as a sanctuary site, although the physiological basis for a blood-testes barrier is not completely understood. Leukemia cells are generally found within the interstitial space, a compartment where MTX concentrations are lower than those in the serum. 26 Although a true isolated extramedullary relapse in the testes may exist, 27 evidence of BM 33 Persistence of MRD, either evaluated with molecular techniques or through flow-cytometry, after induction/consolidation therapy (i.e., after 5 and 12-13 weeks from the beginning of treatment for relapse) also influences prognosis in children with relapsed ALL.
11,34-36 MRD can be detected at the 0.01% level in most patients with either method. 37 Children with MRD levels below 1x10 -3 or 1x10 -4 have been shown to carry a lower risk of recurrence than patients with higher levels of MRD. 11, 34, 36 The predictive value of MRD also in relation to HSCT for childhood relapsed ALL was reported in studies showing that molecular persistence of leukemia before the allograft heralded a high chance of disease recurrence.
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What we do for the treatment of relapsed ALL Standard salvage regimens for relapsed ALL are still mostly based on different combinations of the same agents used in frontline therapy in varying doses and schedules. 6, 10, 33 Many groups adopt treatment strategies consisting of risk-adapted, alternating short-course multiagent systemic and IT chemotherapy, in some cases together with cranial/craniospinal irradiation, and conventional maintenance therapy. Overall, remission can be achieved in more than 70% of early relapses and in up to 96% of late BM relapses. Progression-free survival (PFS) and OS were significantly higher in the mitoxantrone group, and the differences in PFS were mainly related to a decrease in disease events (progression, second relapse, disease-related deaths). The 3-year OS was 69% in the mitoxantrone group (45% in the idarubicin), which overall represented a substantial improvement over preceding trials from the same investigators. 11 This study suggests that, while novel and targeted therapeutic strategies are being developed, a conventional agent, such as mitoxantrone, can confer a significant benefit in children with relapsed ALL. 11 In the ALL-REZ BFM 90 trial, 525 patients stratified into risk groups were enrolled and received alternating short-courses of intensive polychemotherapy (blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy. 6 Multi-agent chemotherapy blocks R1 and R2, deriving from ancestor BFM studies, 12 included 36-hour infusion of MTX, combined with other cytotoxic drugs. Block R3 (including high-dose cytarabine and etoposide) was introduced to improve the outcome compared with historical controls. The probabilities of EFS and OS at 10 years were 30% and 36%, respectively, similar to those of 1 0 previous studies from the same Cooperative Group. 29, 43 Therefore, neither the introduction of block R3 nor the adaptation of chemotherapy intensity improved patient outcome.
In a recent COG report, post-relapse OS was evaluated in 272 patients who had been previously randomly allocated to initial treatment with augmented-or standard-intensity regimen of postinduction intensification (PII). 44 As expected, PFS was worse for early vs. late relapse, marrow vs.
extramedullary site, adolescent vs. younger age and T-ALL vs. BCP-ALL; however, no difference in 3-year OS was found for children given augmented-vs. standard-intensity PII.
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The Italian Pediatric Hematology Oncology Association (AIEOP) has shown efficacy of high-dose idarubicin (40 mg/m 2 ) combined with high-dose cytarabine in patients with HR relapsed ALL. 45 However, idarubicin was not found to be superior to daunorubicin when used at lower dosage (10-12.5 mg/m relapse of ALL should be treated with chemotherapy protocols proved to be effective in reinducing and consolidating a second morphological CR. 6, 11, 44 The algorithm in Figure 1 gives an overview on how we approach management of a patient with first relapse of ALL. We stratify children with relapsed ALL into different risk groups for which diversified protocols are employed. In particular,
we treat HR children with more aggressive chemotherapy schemes. 34, 45, 47 In any case, we recommend that relapsed ALL children be included in prospective, controlled trials. In this regard, the International Cooperative Group on Relapsed ALL (IntReALL) will conduct two randomized trials comparing the classical BFM reinduction therapy with that reported by the UK Children's Cancer Group in SR/IR patients, and with a novel regimen combining clofarabine, etoposide and cyclophosphamide in HR children, respectively. We use MRD measurements to allocate those SR/IR patients with poor blast clearance (around 50% of this subgroup) to allogeneic HSCT. In
particular, we offer transplantation to SR/IR patients with MRD level greater than 1x10 -4 (see also Figure 1 ). Outcome of patients not responding to reinduction treatment has been reported to be dismal. 48 Further therapies with curative intent can induce CR2 but they are associated with high treatment-related morbidity, mortality and minimal survival. Although treatment of these patients has been heterogeneous and customized, we believe that they are candidates for controlled phase I/II trials (see below), and we propose them enrollment in experimental studies both for offering a chance to benefit from new drugs and for fostering drug development for cohorts with better prognosis.
CNS relapse. Radiotherapy together with systemic chemotherapy is universally used for patients experiencing CNS recurrence ( Figure 2 ). The efficacy of this approach has been demonstrated by several studies. In detail, the St Jude's Group reported in 20 children that an intensive retrieval therapy for isolated ALL CNS relapse, consisting of a five-drug reinduction chemotherapy followed by four rotating drug pairs, triple IT therapy and then craniospinal irradiation, led to a second CR in all treated patients. 49 In a POG study, BM relapse in patients with isolated CNS relapse has also been shown to be prevented by administering intensive chemotherapy before delayed craniospinal radiation. 50 In this trial, 83 patients with ALL received systemic and intrathecal chemotherapy for 6 months, followed by craniospinal radiation (24 Gy cranial/15 Gy spinal) and by maintenance treatment. The 4-year EFS for patients with CR1 lasting more than or less than 18 months before CNS relapse was 83% and 46%, respectively. 50 Reduction of the radiation dose to 18 Gy in a subsequent POG trial in 71 patients with BCP-ALL whose initial remission lasted more than 18 months translated into an overall 4-year EFS rate of 78%. 51 Conversely, patients with CR1 of less than 18 month duration had a 4-year EFS of 52%. The BFM group reported a 54% probability of EFS of patients with IEM relapse, regardless of time point of relapse. 6 Together, these data suggest that, while the chance of rescuing patients with late ALL CNS relapse is high, the outcome of
CNS recurrence has to be improved, perhaps also through the use of allogeneic HSCT (see above). Local radiotherapy is delivered after that intensive systemic therapy has been administered with the aim of preventing/treating BM seeding of the leukemia cells (see also Figure 2 ), this strategy being supported also by the observation that sub-microscopic leukemia BM involvement is a frequent finding. With the use of contemporary systemic therapy there is no clear evidence of the superiority of craniospinal irradiation over cranial radiotherapy; we use for all patients with CNS involvement a radiation dose of 18 Gy, which is reduced to 15 Gy in case of prior cranial irradiation (>20 Gy).
Testicular relapse. Either orchiectomy or irradiation have been used as local treatment for children with recurrence of ALL in the testes. 9, 27, 52 There are no data supporting one approach over the other, although, in principle, orchiectomy may provide a greater chance for definitive eradication of testicular disease. We use orchiectomy in case of monolateral testicular involvement; we perform biopsy of the controlateral testis for demonstrating the absence of leukemia localization before administering prophylactic radiotherapy (15 Gy). In case of bilateral testicular localization, we consider either orchiectomy or radiotherapy (24 Gy) as appropriate ( Figure 2 ). If there is no doubt that orchiectomy leads to infertility and abrogates sex hormone production, it has to be underlined that also local radiotherapy at the dosage used for bilateral testicular recurrence is expected to induce infertility and significantly impair hormone production.
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To whom and when we offer allogeneic HSCT in relapsed ALL Allogeneic HSCT is frequently used for pediatric patients with ALL in CR2 after marrow relapse. 6, 31, 32, 40, [54] [55] [56] Several studies have documented that allogeneic HSCT from matched family donors (MFD) offers high chances of rescuing these patients, and the EFS has been reported to be superior to that achieved with second-line chemotherapy treatment. 32, 55 The BFM ALL-REZ-87 1 3 trial indicated that EFS was better after transplantation than after chemotherapy group only in patients with HR or IR ALL relapse. 29 chemotherapy for children with ALL in CR2 documented that the probability of EFS was significantly higher for HR (44% vs. 0%), but not IR (39% vs 49%) patients given the allograft. 31 Cord blood has significantly extended the opportunity to perform HSCT to patients lacking an HLA-matched donor. Published reports have compared the outcome of umbilical cord blood transplantation (UCBT) and UD-BMT in children with hematological malignancies. [59] [60] [61] The
Eurocord group published a study comparing the outcome of matched unrelated BMT (HLA 6 out of 6 matched), either unmanipulated or T-cell-depleted, with HLA-mismatched UCBT. 59 The incidence of relapse was the same in the 3 groups analyzed and the probability of EFS was comparable. Eapen et al. 60 EFS, while an even better outcome was evident for the 35 children given HLA-matched UCBT. 60 These results have been more recently confirmed by Smith and colleagues, who analyzed 87 ALL CR2 children transplanted in a single institution from either HLA-matched siblings, or unrelated donors or with UCB. 61 Ruggeri et al. have recently reported on 170 children with ALL in CR; for the 77 transplanted in CR2, the 4-year EFS was 44% and high levels of MRD before the allograft predicted an increased relapse risk. 40 T-cell-depleted HSCT from an HLA-haploidentical relative (haplo-HSCT) offers an immediate transplant option for patients lacking a matched donor or a suitable cord blood unit. 62 The absence of the T-cell-mediated graft-versus leukemia (GvL) effect has also been thought to render the recipients of a T-cell-depleted allograft more susceptible to leukemia relapse. 62 In our daily practice, we offer allogeneic HSCT to any child with either HR features or poor clearance of blast cells (e.g., high levels of MRD), since these patients (around two thirds of the overall population of relapsed children) have a probability of survival below 30% without Details on what we recommend in terms of cell content and characteristics of UCB units to be employed are summarized in Figure 3 . HLA-haploidentical donors, optimally if NK-alloreactive, can represent a further option in Centers running specific programs. Whatever the type of transplant given, we perform HSCT in children achieving second CR after 2-3 courses of consolidation chemotherapy aimed at obtaining low MRD level, since this portends favorable implications for disease recurrence. [38] [39] [40] Although TBI still represents the golden standard, alternative chemotherapybased regimens should be tested in future controlled trials.
How can we integrate the most promising novel drugs into current regimens for relapsed ALL
After many years in which the portfolio of agents effective against ALL blasts has remained unchanged, the last decade has witnessed the development of novel pharmacological agents, including nucleoside analogues, monoclonal antibodies, new formulations of existing chemotherapeutic agents and targeted molecules, such as tyrosine kinase inhibitors (TKIs) and FMS-related tyrosine kinase 3 (FLT3) inhibitors. 15 The creation in the US of a Pediatric Preclinical Importantly, these schemes had an acceptable safety profile, although adverse events were reported, including fatal infections and cases of veno-occlusive disease of the liver, especially in previously transplanted patients. The UK experience with clofarabine-based regimens for relapsed pediatric ALL formally demonstrated that the probability of response is higher in combination regimens than for single-agent use. 74 In the same trial, clofarabine-based regimens were more effective when given in first relapse, with a CR rate of 86%, compared with 40% and 20% when given in second and third relapse, respectively. 74 Responses were observed in all age groups and in children with adverse cytogenetics, namely MLL rearrangement or a Ph chromosome. 47, [72] [73] [74] In two of the combination studies, the probability of CR was reported to be significantly higher in patients with BCP-ALL than with T-cell ALL. 47, 72 In view of this latter finding, we consider the use of Nelarabine is an inhibitor of purine nucleoside phosphorylase (PNP); in a phase I study, it was given as a consecutive 5-day schedule inducing remarkable responses in patients with T-lineage ALL (54% of CR or partial response after 1-2 courses). 75 In a phase II study restricted to children with refractory T-cell ALL, nelarabine at 1,200 mg/m 2 for 5 consecutive days induced a 35% CR rate in the 79 patients without CNS involvement. 76 A higher rate was achieved in patients who were in first relapse (46%), compared with those in second relapse (25%) or with CNS disease (21%).
The US FDA approved nelarabine on October 2005 for the third-line treatment of patients with Tcell ALL/lymphoma. 77 Recently, the COG AALL00P2 trial, a two-stage pilot study, assessed the feasibility and safety of adding nelarabine to an intensive modified BFM 86 chemotherapy regimen in children with newly diagnosed, high-risk T-ALL. This study showed that nelarabine is well tolerated and gives encouraging results in pediatric patients with T-ALL, particularly those with a slow early response, who historically have a dismal prognosis. 78 Thus, we believe that combination schemes including nelarabine have to be implemented and tested for children with relapsed T-cell ALL.
Monoclonal antibodies. Epratuzumab is a humanized monoclonal antibody targeting the CD22
antigen, highly expressed in the majority of BCP-ALL. 79 This compound has been employed both in a window therapy and in combination with standard reinduction chemotherapy, in a pilot study enrolling 15 pediatric patients affected by BCP-ALL with BM relapse. 80 Nine of these fifteen patients achieved CR, seven with negativity of MRD. 80 The efficacy of epratuzumab will be further tested in a randomized trial being conducted by the IntReALL group and aimed at evaluating its role in reducing MRD levels in SR patients, thus decreasing the number of children eligible for HSCT. Anti-CD22 immunotoxins are under development to improve the efficacy of this antibody.
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Blinatumomab is a murine, single-chain antibody construct belonging to a new class of bi-specific T-cell engagers (BiTE) and designed to link CD19-expressing B cells and T cells. This synapsis results in cytotoxic T-cell responses (CTL) against CD19-expressing cells. 81, 82 In vitro data indicated that CD19 + lymphoma and leukemia cell lines are extremely sensitive to blinatumomabmediated cytotoxicity. 81, 82 A phase I study, conducted in 38 adults with either relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL), has demonstrated a dose-dependent efficacy of blinatumomab. 83 The drug was effective in killing lymphoma cells not only in lymphoid organs, but also in the BM.
The German Multi-center Study Group on Adult ALL (GMALL) evaluated the safety and efficacy of blinatumomab in 21 adults with BCP-ALL and MRD persistence/relapse after induction and consolidation therapy. 84 Patients received a 28-day continuous intravenous infusion of blinatumomab at 15
/day followed by a treatment-free period of 2 weeks. Responders either received three additional consolidation cycles of blinatumomab or were given HSCT. Sixteen patients became MRD negative. Remarkably, 12 of them had been molecularly refractory to previous chemotherapy. 84 This study suggests that blinatumomab has the potential to induce, as a single agent, durable remissions in molecularly refractory BCP-ALL.
More recently, 18 adult patients with relapsed/refractory BCP-ALL were given blinatumomab in an exploratory phase II trial. 85 The drug was administered by continuous infusion for 28 days followed by a 14-day treatment-free interval at 3 dose levels of 5-30 μg/m 2 /day. Twelve of them (67%) reached CR within the first 2 cycles of treatment. Of these 12 responding patients, 75% had complete hematologic recovery and all reached MRD negativity within the first 2 cycles. This study indicates that the drug is also effective in ALL adults with either overt relapse or hematological resistance to conventional treatment.
Available data on the safety and efficacy of blinatumomab in children are much more limited.
Handgretinger and Colleagues reported on three pediatric patients with ALL who relapsed after
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From allogeneic HSCT. 86 Children were given the drug at 15 μ g/m²/day for at least four weeks. All patients showed molecular CR after four weeks of treatment. Safety was described as acceptable, without treatment interruptions or discontinuations due to adverse events. 86 Further studies on the drug in relapsed ALL are ongoing.
Bortezomib is a proteasome inhibitor, which renders leukemic cells more sensitive to the apoptotic effects of chemotherapy. Bortezomib is synergistic with dexamethasone and additive with cytarabine, doxorubicin, asparaginase and vincristine. 14 The efficacy of bortezomib with cytotoxic drugs used for reinducing remission in ALL patients (namely, dexamethasone, vincristine, pegylated asparaginase and doxorubicin) has been recently reported in a phase I study. 87 An extended phase II study enrolling 22 children was recently reported by the TACL (Therapeutic Advances in Childhood Leukemia) consortium. All patients had failed 2-3 prior regimens; CR and
CRp were obtained in 73% of patients, this percentage increasing to 80% in BCP-ALL. 88 These results led to a premature discontinuation of the trial for evident superiority with respect to historical results.
Targeted molecular treatments are a novel and promising approach in the management of ALL. The most successful example of molecularly targeted therapy in ALL is that of the TKIs. Imatinib mesylate proved to be effective in improving the outcome of childhood Philadelphia (Ph)-positive ALL 89 and it can certainly be employed in the context of relapsed ALL, provided that molecular studies on relapsed samples do not show mutations conferring resistance to the drug. Dasatinib and nilotinib have been shown to be active and efficacious in imatinib-resistant Ph+ malignancies and dasatinib is replacing imatinib in several Ph+ ALL regimens for adults. 90, 91 The use of these novel TKIs, both in reinduction and for preventing leukemia recurrence after an allograft, remains to be tested in future trials.
FLT3 is frequently over-expressed in MLL-rearranged ALL, in c-kit (CD117)-positive T-cell ALL We recommend that any child with second relapse of ALL or refractory disease be included into experimental trials aimed at testing/validating safety and efficacy of novel agents. More specifically, whenever feasible, each child with ALL in second relapse or resistant to either firstline or second-line therapy treated at our Institution is enrolled in phase I/II trials with one of the drugs discussed above. Indeed, we believe that the development of these novel approaches holds great promise for the future and it is desirable that the most successful of these compounds be soon incorporated into the first-line treatment of patients with HR relapsed ALL.
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